erlotinib [Tarceva] + gemcitabine
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Aug 1, 2007 → Apr 1, 2009
NCT ID
NCT00642733About erlotinib [Tarceva] + gemcitabine
erlotinib [Tarceva] + gemcitabine is a approved stage product being developed by Roche for Pancreatic Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00642733. Target conditions include Pancreatic Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Pancreatic Cancer were approved
Approved (8) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00642733 | Approved | Terminated |
Competing Products
20 competing products in Pancreatic Cancer